Last updated: February 5, 2021
Sponsor: Allergy Therapeutics
Overall Status: Completed
Phase
N/A
Condition
Respiratory Syncytial Virus (Rsv) Infection
Allergy (Pediatric)
Eye Disorders/infections
Treatment
N/AClinical Study ID
NCT04389034
PQ EAST V1.0
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients ≥ 18 years
- Diagnosis of IgE-mediated rhinitis, conjunctivitis and bronchial asthma on grassand/or tree pollen
- completed allergen-specific immunotherapy with Pollinex Quattro with tree and/or grasspollen extracts or their mixtures according to SMPC effective during immunotherapy
Exclusion
Exclusion Criteria:
- Contraindication according to Summary of Product Characteristics (SMPC) effectiveduring immunotherapy
- no additional allergen-specific immunotherapy with another product than PollinexQuattro
Study Design
Total Participants: 113
Study Start date:
April 22, 2020
Estimated Completion Date:
October 05, 2020
Study Description
Connect with a study center
Outpatient Center Dr Stollewerk/Niebecker
Cologne,
GermanySite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.